Posted on 04/11/2009 in Scientific Thermo Fisher Scientific has announced the launch of its latest biomarker test for the European market.
Its Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI), or heart attacks, was developed by Brahms AG, which the company recently acquired.
Copeptin is a patented biomarker for AMI and is detectible using a simple blood test that, in combination with a Troponin biomarker test, allows doctors to evaluate the possible risk of heart attack within a matter of minutes.
Dr Yuh-Geng Tsay, head of Thermo Fisher Scientific's specialty diagnostics business, stated: "The Copeptin assay shows that we're having an impact by helping physicians to be more effective at diagnosing disease, which ultimately improves patient health and also lowers the cost of care."
Thermo Fisher Scientific announced that its acquisition of Brahms AG had been completed last month.
It paid a total of 330 million euros (305 million pounds) for the organisation, which generated revenues of 75 million euros in 2008.
Other news stories from 04/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
